ReportWire

Tag: Medical research

  • Trump admin settles lawsuit, agrees to restore deleted DEI, gender health web pages

    [ad_1]

    NEWYou can now listen to Fox News articles!

    A large Washington-based medical association announced Tuesday they had reached a settlement with the Trump administration requiring the restoration of dozens of public health web pages and datasets tied to diversity, equity and inclusion (DEI) and gender identity.

    The Department of Health and Human Services (HHS) did not comment on the settlement, but told Fox News Digital it remains “committed to its mission of removing radical gender and DEI ideology from federal programs, subject to applicable law, to ensure taxpayer dollars deliver meaningful results for the American people.”

    The Washington State Medical Association and Doctors for America sued HHS and other agencies in May after the Trump administration, following executive orders in January, directed the removal of hundreds of web pages and datasets that referenced gender identity or diversity, equity and inclusion, LGBTQ+ health, racism, vaccines, opioid use, and Biden-era abortion policies on federal health websites.

    TRUMP ADMINISTRATION WINS SUPREME COURT FIGHT TO SLASH NIH MEDICAL RESEARCH GRANTS TIED TO DEI, LGBTQ STUDIES

    Medical groups sued the Trump administration in May after hundreds of web pages were removed following Trump’s executive orders. (Getty Images)

    The settlement requires the Trump administration to restore the deleted health web pages, though officials have not said when they will go back online. Once reposted, the guidance will again be available to doctors and patients as the president continues his push to terminate federal DEI programs.

    As of Tuesday, the medical association said the defendants “have agreed to restore webpages and data that were wrongfully deleted, ensuring that these critical resources are once again available to physicians, scientists, medical professionals, and the American public.”

    “I am extremely proud of the health care community in Washington state and our partners in this case for pushing back on this egregious example of government overreach,” Dr. John Bramhall, president of the WSMA, said in a statement. 

    In February, Bush-appointed U.S. District Judge John Bates issued a temporary restraining order requiring the content be restored while the case proceeded. The parties later agreed to pause the case in August while negotiating a resolution, leading to this week’s announced settlement.

    BIDEN-APPOINTED JUDGE HALTS TRUMP HHS OVERHAUL AFTER DEMOCRAT-LED LAWSUIT

    President Donald Trump signs the order surrounded by female athletes

    President Donald Trump, joined by female athletes, signed the “No Men in Women’s Sports” executive order in the East Room at the White House on Feb. 5, 2025 in Washington, DC. (Andrew Harnik/Getty Images)

    Court records filed Aug. 15 show both sides told the judge they had reached a settlement “in principle” and asked for a 45-day pause to finalize the deal. Biden-appointed U.S. District Judge Lauren King granted the request, formally putting the case on hold while the agreement is implemented.

    Defendants in the lawsuit include HHS Secretary Robert F. Kennedy Jr., Centers for Disease Control and Prevention (CDC) Acting Director Matthew Buzzelli, the National Institutes of Health (NIH) Director Jay Bhattacharya, the Food and Drug Administration (FDA) Commissioner Martin A. Makary, and Health Resources and Services Administration (HRSA) Administrator Thomas J. Engels. 

    Web pages from the FDA, NIH, HRSA, Department of Justice (DOJ) and Department of Veterans Affairs (VA) were also removed, according to the medical group’s complaint.

    Among the removals included the CDC’s page on supporting LGBTQ+ youth and another with facts about LGBT youth suicide. The NIH took down its Sexual & Gender Minority Research Office site, while the HHS erased an entire web page on abortion-related resources. The VA also removed a page offering guidance on medical care for LGBTQ+ veterans.

    REAGAN-NOMINATED FEDERAL JUDGE ACCUSES TRUMP ADMIN OF ‘DISCRIMINATION’ WITH CUTS TO NIH DIVERSITY GRANTS

    HHS Secretary RFK, Jr. in the Oval Office during a confirmation hearing for Dr. Mehmet Oz.

    Health and Human Services Secretary Robert F. Kennedy Jr. is one of the defendants in the medical web page lawsuit against the Trump administration. (Andrew Harnik/Getty Images)

    The Washington State Medical Association represents more than 13,000 health officials and medical students across all specialties in Washington state, according to its website.

    CLICK HERE TO GET THE FOX NEWS APP

    In January, the Trump administration began purging web pages not aligned with the president’s executive orders titled, “Defending Women from Gender Ideology Extremism and Restoring Biological Truth to the Federal Government” and “Ending Radical and Wasteful Government DEI Programs and Preferencing.” The orders directed federal agencies to recognize sex as only male and female and terminated DEI initiatives.

    [ad_2]

    Source link

  • Halsey bids big and Colman Domingo hosts Venice amfAR gala

    [ad_1]

    VENICE — Singer Halsey bid for the top lot at the amfAR Venezia fundraiser Sunday and spoke on the red carpet about how the charitable foundation’s work has helped her personally.

    Hosted by an impassioned Colman Domingo in a bright green custom Valentino jacket, the event took place at the Arsenale during the Venice Film Festival.

    More low key and intimate than it’s Cannes Film Festival counterpart, the event still attracted its share of celebrities including Jude Law, in Venice to promote “The Wizard of the Kremlin,” in which he stars as Putin.

    The evening started with champagne, canapés, Italian spritz and negronis on the waterfront terrace as a DJ spun tunes and guests viewed the artwork to be auctioned off later in the evening.

    As those attending were seated for a traditional Venetian dinner of Ombrina fish, Paris Jackson performed an acoustic set on stage.

    During the dinner there was a live auction of contemporary artworks, jewellery and destination vacations raising $3.4 million.

    Director Julian Schnabel, who will present his latest film “In the Hand of Dante” at the festival next week, donated one of his sought-after plate portraits (a portrait of the winning bidder painted on broken dishes.) Introduced on stage by Jude Law, he decided on the spot to offer up two portraits to the two highest bidders raising 500,000 euros ($586,000) for each, one of which went to singer Halsey.

    Talking earlier on the red-carpet Halsey revealed how amfAR had helped her in a very personal way:

    “I, a couple years ago got diagnosed with two pretty severe autoimmune diseases and amfAR also contributes to autoimmune and cancer research. So the work they do allows people like me with less access than me to get treatment that they really, really need to live the lives that they deserve to live. So, it’s never been closer to home that it is right now.”

    Schnabel was also presented with an Award of Inspiration from the charity in recognition of his longstanding commitment to amfAR’s lifesaving research.

    The night ended with a high octane performance from pop star Ava Max, who got everyone on their feet dancing and then it was a rush to a sea of water taxis, waiting to whisk the guests off back to their Venice hotels or on to the after-party.

    amfAR, The Foundation for AIDS Research, is a nonprofit organization dedicated to the support of AIDS research, HIV prevention, treatment education, and advocacy. Since 1985, amfAR has raised nearly $950 million in support of its programs.

    [ad_2]

    Source link

  • CDC Director Susan Monarez refuses to be fired as other officials call it quits

    [ad_1]

    NEWYou can now listen to Fox News articles!

    Longtime government scientist Susan Monarez is refusing to leave her position as director of the Centers for Disease Control and Prevention (CDC) after the Department of Health and Human Services (HHS) announced she had been removed from the role less than a month after she was sworn in.

    Attorneys Mark Zaid and Abbe Lowell said they are representing Monarez and claimed she “has neither resigned nor yet been fired.”

    The attorneys released a statement on social media, claiming HHS and Secretary Robert F. Kennedy Jr. are weaponizing public health for political gain and putting millions of American lives at risk. 

    “When CDC Director Susan Monarez refused to rubber-stamp unscientific, reckless directives and fire dedicated health experts she chose protecting the public over serving a political agenda,” the statement said. “For that, she has been targeted. Dr. Monarez has neither resigned nor received notification from the White House that she has been fired, and as a person of integrity and devoted to science, she will not resign.”

    ABOUT 600 CDC WORKERS TERMINATED AFTER COURT CLEARS PART OF TRUMP ADMIN RESTRUCTURING PLAN

    Susan Monarez is seen here testifying during her June confirmation hearing in front of the Senate Committee on Health, Education, Labor, and Pensions in the Dirksen Senate Office Building on June 25, 2025. (Kayla Bartkowski/Getty Images)

    The Washington Post reported that sources within the CDC, who spoke on the condition of anonymity, said HHS leaders, including Kennedy, sought to get Monarez to commit to rescinding approvals for certain COVID-19 vaccines. When Monarez did not immediately commit, she was told by administration officials that she either needed to resign or be fired. 

    Sources also claimed that she then attempted to involve chairman of the Senate’s top health committee, Sen. Bill Cassidy, R-La. The move reportedly further angered Kennedy. 

    When reached for comment, a spokesperson for the HHS directed Fox News Digital to the agency’s response shared on its official X account.

    “Susan Monarez is no longer director of the Centers for Disease Control and Prevention,” HHS said. “We thank her for her dedicated service to the American people. Secretary Kennedy has full confidence in his team at the CDC who will continue to be vigilant in protecting Americans against infectious diseases at home and abroad.”

    The White House did not respond to Fox News Digital’s inquiries about the matter.

    Monarez was tapped by the Trump administration to lead the CDC after its initial nominee, Dave Weldon, was withdrawn from contention in March, amid fears he might not garner enough support in the Senate to be confirmed. Shortly after Weldon stepped down, Monarez was formally nominated to be the CDC’s permanent director and was eventually confirmed in the final week of July.

    During Monarez’s confirmation, she expressed support for vaccines and told lawmakers she has “not seen a causal link between vaccines and autism.”

    MEDICAL GROUP GOES AGAINST CDC, RECOMMENDS COVID SHOTS FOR YOUNG KIDS 

    CDC logo behind syringe and vial with label that reads, Vaccine COVID-19

    In this photo illustration a syringe and an illustrative vial with COVID-19 coronavirus vaccine seen in front of the Centers for Disease Control and Prevention (CDC) logo. ( Pavlo Conchar/SOPA Images/LightRocket via Getty Images)

    Prior to Monarez’s Senate confirmation, CDC directors did not typically require Senate approval, but that changed in 2022 when Congress passed a law making it necessary. Monarez was the first-ever Senate-confirmed CDC director in the agency’s history.

    Monarez was also the first CDC director without a medical degree in more than seven decades. However, she does hold a PhD in microbiology and immunology.

    After getting her doctorate, Monarez entered the federal government, where she found herself in roles at the White House’s Office of Science and Technology Policy, the National Security Council, the Department of Homeland Security and the Advanced Research Projects Agency for Health (ARPA-H). Her bio on the CDC’s website states that she worked on “leading efforts to enhance the nation’s biomedical innovation capabilities, including combating antimicrobial resistance, expanding the use of wearables to promote patient health, ensuring personal health data privacy, and improving pandemic preparedness.”

    CLICK HERE TO GET THE FOX NEWS APP

    Trump/Monarez split

    President Donald Trump (left) nominated Susan Monarez (right) to lead the CDC. She was subsequently confirmed the last week of July, before being ousted this week, less than a month later. (Getty Images; U.S. Centers for Disease Control and Prevention)

    Hours after the news that Monarez would no longer head the CDC, sources confirmed to Fox News Digital that at least three other top CDC officials tendered their resignations, including the CDC’s director of its National Center for Immunization and Respiratory Diseases, Demetre Daskalakis, the director of the National Centers for Emerging and Zoonotic Infectious Disease, Dr. Daniel Jernigan, and the CDC’s chief medical officer, Debra Houry. 

    Resignation letters coming out from these officials have reportedly cited the Trump administration’s approach to vaccines, as well as the administration’s budget cuts.

    Fox News’ David Lewkowict contributed to this report.

    [ad_2]

    Source link

  • Supreme Court OKs Trump’s cuts to research funding

    [ad_1]

    BOSTON — Massachusetts leaders are blasting a U.S. Supreme Court court ruling that will allow the Trump administration to claw back nearly $800 million in federal grants for medical and scientific research, saying the move will hurt patients and institutions who rely on the money for lifesaving work.

    A divided Supreme Court on Thursday issued an unsigned order allowing the National Institutes of Health, the largest public funding source for biomedical research in the world, to terminate federal grants linked to diversity, equity and inclusion initiatives.


    This page requires Javascript.

    Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

    kAm%96 dc CF=:?8 3J E96 4@FCE’D 4@?D6CG2E:G6 >2;@C:EJ @G6CEFC?65 2 yF?6 564:D:@? 3J &]$] s:DEC:4E r@FCE ;F586 (:==:2> *@F?8 😕 q@DE@? E92E 3=@4<65 E96 42?46==2E:@? @7 E96 8C2?ED 7@C 5:G6CD:EJ :?:E:2E:G6D 2D “G@:5 2?5 :==682=” 3642FD6 E96 492?86D H6C6 32D65 @? 5:D4C:>:?2E:@? 282:?DE C24:2= >:?@C:E:6D 2?5 E96 {vq%”Z 4@>>F?:EJ]k^Am

    [ad_2]

    By Christian M. Wade | Statehouse Reporter

    Source link

  • FACT FOCUS: RFK Jr.’s reasons for cutting mRNA vaccine not supported by evidence

    [ad_1]

    Although mRNA vaccines saved millions of lives during the COVID-19 pandemic, U.S. Health Secretary Robert F. Kennedy Jr. incorrectly argued they are ineffective to justify the Department of Health and Human Service’s recent decision to cancel $500 million in government-funded research projects to develop new vaccines using the technology.

    The longtime vaccine critic said in an X video posted Tuesday evening that mRNA vaccines do not adequately prevent upper respiratory infections such as COVID-19 and the flu, advocating instead for the development vaccines that use other processes.

    COVID-19 is the only virus for which real-world data on mRNA vaccine effectiveness is currently available, as mRNA vaccines for other diseases, including the flu, are still under development. The two scientists whose discoveries enabled the creation of mRNA vaccines against COVID-19 won a Nobel Prize in 2023 for their work.

    Kennedy’s claim ignores how mRNA vaccines work, according to experts. They prevent against severe infection and death, but cannot completely prevent an infection from occurring in the first place. Plus, years of research supports the effectiveness of COVID-19 vaccines that use mRNA technology.

    Here’s a closer look at the facts.

    KENNEDY: “As the pandemic showed us, mRNA vaccines don’t perform well against viruses that infect the upper respiratory tract.”

    THE FACTS: His claim is contradicted by scientific evidence. Countless studies show that vaccinated individuals fare far better against COVID-19 infections than those who are unvaccinated, while others have estimated that COVID-19 vaccines prevented millions of deaths during the global pandemic. The mRNA vaccines do not prevent respiratory diseases entirely, experts say. Rather, they can prevent more serious illness that leads to complications and death. For example, an mRNA vaccine against COVID-19 may prevent an infection in the upper respiratory tract that feels like a bad cold from spreading to the lower respiratory tract, where it could affect one’s ability to breathe.

    “A vaccine cannot block a respiratory infection,” said Dr. Jake Scott, an infectious diseases physician and clinical associate professor at Stanford University School of Medicine. “That’s never been the standard for a respiratory virus vaccine. And it’s never been the expectation, and it’s never been that realistic.” He called Kennedy’s claim “misguided.”

    Jeff Coller, a professor of RNA biology and therapeutics at Johns Hopkins University, had a similar outlook.

    “Vaccinations don’t have to be neutralizing, meaning that you’re not going to get COVID,” he said. “But the important part of a vaccination is that they reduce hospitalization and death. And a reduction in hospitalization and death is proof of an effective vaccine.”

    HHS officials did not immediately respond to a request for comment.

    Vaccines have traditionally required growing viruses or pieces of viruses called proteins and then purifying them. Then a small dose of the vaccine is injected to train the body how to recognize when a real infection hits so it’s ready to fight back. But this method takes a long time. The mRNA technology speeds up the process and allows existing vaccines to be updated more quickly.

    The “m” in mRNA stands for messenger because the vaccine carries instructions for our bodies to make proteins. Scientists figured out how to harness that natural process for vaccines by making mRNA in a lab. They take a snippet of the genetic code that carries instructions for making the protein they want the vaccine to target. Injecting that snippet instructs the body to become its own mini-vaccine factory, making enough copies of the protein for the immune system to recognize and react.

    Scott explained that mRNA vaccines are not a “magic force field” that the immune system can use to block an infection, as it can’t detect whether a virus is nearby. It can only respond to a virus that has already entered the body. In the case of COVID-19, this means that the virus could cause an upper respiratory tract infection — a cold, essentially — but would be significantly less likely to cause more severe consequences elsewhere.

    Myriad studies on the effectiveness of COVID-19 vaccines have been published since they first became available in late 2020. Although protection does wane over time, they provide the strongest barrier against severe infection and death.

    For example, a 2024 study by the World Health Organization found COVID-19 vaccines reduced deaths in the WHO’s European region by at least 57%, saving more than 1.4 million lives since their introduction in December 2020.

    A 2022 study published in the journal Lancet Infectious Diseases found that nearly 20 million lives were saved by COVID-19 vaccines during their first year. Researchers used data from 185 countries to estimate that vaccines prevented 4.2 million COVID-19 deaths in India, 1.9 million in the United States, 1 million in Brazil, 631,000 in France and 507,000 in the United Kingdom. The main finding — that 19.8 million COVID-19 deaths were prevented — is based on estimates of how many more deaths than usual occurred during the time period. Using only reported COVID-19 deaths, the same model yielded 14.4 million deaths averted by vaccines.

    Another 2022 study, published in The New England Journal of Medicine, reported that two mRNA vaccines were more than 90% effective against COVID-19.

    Operation Warp Speed, the federal effort to facilitate the development and distribution of a COVID-19 vaccine, began under the first Trump administration.

    “What I don’t understand is why is President Trump is allowing RFK Jr. to undermine his legacy that led to a medical intervention that literally saved millions of lives?” Coller said. “Why is Trump allowing RFK to undermine U.S. leadership in biomedical research and drug development?”

    ___

    Find AP Fact Checks here: https://apnews.com/APFactCheck.

    [ad_2]

    Source link

  • Alpha Genesis Proposes Innovative Management Model to Transform National Primate Research Centers

    [ad_1]

    The plan would enhance the efficiency of taxpayer-funded biomedical research amid government restructuring.

    Alpha Genesis, a premier provider of primate research models and a leader in ethical biomedical research, has announced its readiness to manage and optimize the operations of National Primate Research Centers (NPRCs) across the United States. With its expertise in efficient facility management, cutting-edge scientific research, and industry-leading animal welfare practices, Alpha Genesis aims to enhance the performance of these vital research institutions while ensuring long-term financial sustainability.

    By leveraging its operational efficiency and private-sector expertise, Alpha Genesis believes it can improve research output, streamline administrative processes, and turn NPRCs into financially viable entities without compromising their critical role in advancing medical science.

    A Vision for Sustainable and Profitable Primate Research

    The current NPRC model, funded primarily by federal grants, often faces financial strain, bureaucratic inefficiencies, and administrative hurdles that hinder scientific progress. Alpha Genesis proposes a public-private partnership model that would:

    • Increase Research Productivity: By implementing advanced management techniques and streamlining operations, Alpha Genesis would enhance the research capabilities of NPRCs, ensuring more discoveries in fields such as infectious diseases, neuroscience, and vaccine development.

    • Ensure Long-Term Financial Stability: Through strategic business management and diversified funding sources, Alpha Genesis would transition NPRCs into self-sustaining operations while maintaining their scientific integrity.

    • Enhance Animal Welfare Standards: With a proven track record in primate care, Alpha Genesis would implement the latest advancements in enrichment, housing, and veterinary care to ensure the highest ethical standards.

    • Reduce Administrative Burdens: By introducing private-sector efficiency, Alpha Genesis would cut excessive costs and allow researchers to focus on groundbreaking studies rather than bureaucratic challenges.

    “Alpha Genesis has the experience, expertise, and vision to modernize the way National Primate Research Centers operate,” said Dr. Greg Westergaard, CEO at Alpha Genesis. “By applying a business-minded approach while maintaining a strong commitment to animal welfare and scientific integrity, we can ensure that these research centers continue to drive medical breakthroughs without the financial instability they currently face.”

    A Call for Collaboration

    Alpha Genesis invites discussions with federal agencies, policymakers, and research institutions to explore this transformative approach to managing NPRCs. The organization is confident that by integrating best practices from both the private and public sectors, it can create a more effective and sustainable research ecosystem that benefits both science and society.

    For more information about Alpha Genesis and its vision for the future of primate research, please visit www.alphagenesisinc.com or contact info@alphagenesisinc.com / 843-589-5190.

    Contact Information

    Dr. Greg Westergaard
    President and CEO
    gwprimate@alphagenesisinc.com
    843-589-5190

    Source: Alpha Genesis, Inc.

    [ad_2]

    Source link

  • Medicare Advantage shopping season arrives with a dose of confusion and some political implications

    Medicare Advantage shopping season arrives with a dose of confusion and some political implications

    [ad_1]

    Thinner benefits and coverage changes await many older Americans shopping for health insurance this fall. That’s if their plan is even still available in 2025.

    More than a million people will probably have to find new coverage as major insurers cut costs and pull back from markets for Medicare Advantage plans, the privately run version of the federal government’s coverage program mostly for people ages 65 and older.

    Industry experts also predict some price increases for Medicare prescription drug plans as required coverage improvements kick in.

    Voters will learn about the insurance changes just weeks before they pick the next president and as Democrat Kamala Harris campaigns on promises to lower health care costs. Early voting has already started in some states.

    “This could be bad news for Vice President Harris. If that premium is going up, that’s a very obvious sign that you’re paying more,” said Massey Whorley, an analyst for health care consulting company Avalere. “That has significant implications for how they’re viewing the performance of the current administration.”

    Insurance agents say the distraction of the election adds another complication to an already challenging annual enrollment window that starts next month.

    Insurers are pulling back from Medicare Advantage

    Medicare Advantage plans will cover more than 35 million people next year, or around half of all people enrolled in Medicare, according to the federal government. Insurance agents say they expect more people than usual will have to find new coverage for 2025 because their insurer has either ended a plan or left their market.

    The health insurer Humana expects more than half a million customers — about 10% of its total — to be affected as it pulls Medicare Advantage plans from places around the country. Many customers will be able to transfer to other Humana plans, but company leaders still anticipate losing a few hundred thousand customers.

    CVS Health’s Aetna projects a similar loss, and other big insurers have said they are leaving several states.

    Insurers say rising costs and care use, along with reimbursement cuts from the government, are forcing them to pull back.

    Some people can expect a tough search

    When insurers leave Medicare Advantage markets, they tend to stop selling plans that have lower quality ratings and those with a higher proportion of Black buyers, said Dr. Amal Trivedi, a Brown University public health researcher.

    He noted that market exits can be particularly hard on people with several doctors and on patients with cognitive trouble like dementia.

    Most markets will still have dozens of plan choices. But finding a new option involves understanding out-of-pocket costs for each choice, plus figuring out how physicians and regular prescriptions are covered.

    “People don’t like change when it comes to health insurance because you don’t know what’s on the other side of the fence,” said Tricia Neuman, a Medicare expert at KFF, a nonprofit that researches health care.

    Plans that don’t leave markets may raise deductibles and trim perks like cards used to pay for utilities or food.

    Those proved popular in recent years as inflation rose, said Danielle Roberts, co-founder of the Fort Worth, Texas, insurance agency Boomer Benefits.

    “It’s really difficult for a person on a fixed income to choose a health plan for the right reasons … when $900 on a flex card in free groceries sounds pretty good,” she said.

    Don’t “sleep” on picking a Medicare plan

    Prices also could rise for some so-called standalone Part D prescription drug plans, which people pair with traditional Medicare coverage. KFF says that population includes more than 13 million people.

    The Centers for Medicare and Medicaid Services said Friday that premiums for these plans will decrease about 4% on average to $40 next year.

    But brokers and agents say premiums can vary widely, and they still expect some increases. They also expect fewer plan choices and changes to formularies, or lists of covered drugs. Roberts said she has already seen premium hikes of $30 or more from some plans for next year.

    Any price shift will hit a customer base known to switch plans for premium changes as small as $1, said Fran Soistman, CEO of the online insurance marketplace eHealth.

    The changes come as a congressional-approved coverage overhaul takes hold. Most notably, out-of-pocket drug costs will be capped at $2,000 for those on Medicare, an effort championed by Democrats and President Joe Biden in 2022.

    In the long run, these changes will lead to a “much richer benefit,” Whorley said.

    KFF’s Neuman noted that the cap on drug costs will be especially helpful to cancer patients and others with expensive prescriptions. She estimates about 1.5 million people will benefit.

    To ward off big premium spikes because of the changes, the Biden administration will pull billions of dollars from the Medicare trust fund to pay insurers to keep premium prices down, a move some Republicans have criticized. Insurers will not be allowed to raise premium prices beyond $35 next year.

    People will be able to sign up for 2025 coverage between Oct. 15 and Dec. 7. Experts say all the potential changes make it important for shoppers to study closely any new choices or coverage they expect to renew.

    “This is not a year to sleep on it, just re-enroll in the status quo,” said Whorley, the health care analyst.

    ___

    The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

    [ad_2]

    Source link

  • WNBA star Breanna Stewart raises awareness for marrow donor program after death of father-in-law

    WNBA star Breanna Stewart raises awareness for marrow donor program after death of father-in-law

    [ad_1]

    NEW YORK — Breanna Stewart lost her father-in-law, Josep Xargay, to cancer nearly a year ago.

    Stewart is now helping raise awareness for the disease, joining the national marrow donor program.

    “It was pretty deep,” Stewart said in an interview with the AP, pausing for a moment to regain her composure, about her loss. “I don’t think it ever got to the point where he could get on a transplant list or anything. I don’t know if I’ll be able to donate at some point, but just doing what I can to help spread the word.”

    Stewart took part Saturday in an event in New York called NMDP Unite, which falls on the global celebration of World Marrow Donor Day. The event helped raise funds for NMDP’s patient assistance program and blood stem cell research initiatives.

    She shook hands and posed for photos with the attendees and also took a swab to join the NMDP registry.

    The Liberty star also recently met after a game with Brian Kevan, a New York firefighter who was at 9/11. Kevan had cancer and now is free of it thanks to a blood stem cell donation he received. The pair reconnected on Saturday at the event.

    “It’s really inspirational and something I wanted to be a part of,” Stewart said. “He was a firefighter in 9/11, which is even more inspiring and incredible.”

    Stewart said she was only seven years old on Sept. 11, but remembers vividly the emotions of the day.

    “We were in school and we were supposed to watch something on TV that day, and all of a sudden, like, the teachers were just getting, like, really emotional.,” she recalled. “We couldn’t watch anything. We got sent home early, and I came home and my mom was on her on the couch crying, watching the news.”

    Stewart also met that night after the Liberty game another cancer patient who attended UConn with her. That patient hasn’t required a transplant yet.

    “Hopefully I can inspire them as they’re inspiring me and, you know, when you get this opportunity to meet people who are really fighting for their lives, it puts life into perspective,” Stewart said.

    The Liberty forward said with the anniversary of her father-in-law’s death coming up it will be hard on their family.

    “I’ll continue to get through it by helping others and this was one way,” she said.

    ___

    AP WNBA: https://apnews.com/hub/wnba-basketball

    [ad_2]

    Source link

  • People with ADHD are turning to AI apps to help with tasks. Experts say try it cautiously

    People with ADHD are turning to AI apps to help with tasks. Experts say try it cautiously

    [ad_1]

    Becky Litvintchouk didn’t think she’d be able to manage the mountain of tasks needed to become an entrepreneur. Every other part of her life has been overwhelming because of ADHD, which can impact her ability to concentrate.

    So, she turned to AI. The app Claude helps her decide which contracts made the most sense for her hygienic-wipes business, GetDirty, without having to read them word for word. She also created business plans by telling the generative AI bot what her goals were and having it create steps for her to get there.

    “It’s been just massively instrumental. I probably would not be where I am today,” she said of using AI for about two years.

    Experts say generative AI tools can help people with attention deficit hyperactivity disorder — who experience difficulties with focusing, organizing and controlling impulses — to get through tasks quicker. But they also caution that it shouldn’t replace traditional treatment for ADHD, and also expressed concerns about potential overreliance and invasion of privacy.

    Will apps replace ADHD treatment?

    Emily Kircher-Morris, a counselor who focuses on neurodivergent patients, said she’s seen the tools be useful to her clients with ADHD. She even uses them herself since she has ADHD.

    Her clients, she said, seem to have varying levels of comfort with the idea of using AI. But for those who take to the technology, “it really can help to hook people in, like, ‘Oh, this is kind of a fancy new thing that catches my interest. And so I really want to dig in and explore it.’”

    This article is part of AP’s Be Well coverage, focusing on wellness, fitness, diet and mental health. Read more Be Well.

    She also said it’s good to use caution. John Mitchell, an associate professor at Duke University School of Medicine, added that AI apps should be used more as “one tool in a toolbox” instead of replacing traditional treatments such as developing organizational skills or taking prescription medications.

    “If you’re kind of treading water in your job and AI’s a life preserver, well, that’s great you’re staying above water, but, you know, you still don’t know how to swim,” he said.

    What else can the apps do?

    Litvintchouk, a married mother of four living in New York City, dropped out of high school and left the workforce — all things that research shows are more likely to happen to people with ADHD, putting them at higher risk of economic instability.

    Aside from helping with her business, she uses ChatGPT to help with grocery shopping — another thing that can be fraught for people with ADHD because of the organization and planning skills needed — by having it brainstorm easy-to-prepare recipes with a corresponding grocery list.

    When she shared her technique with another mom who also has ADHD, she felt more people needed to know about it, so she started creating videos on TikTok about various AI tools she uses to help manage her ADHD struggles.

    “That’s when I was like, you know what? I need to, like, educate people,” she said.

    Generative AI tools can help people with ADHD break down big tasks into smaller, more manageable steps. Chatbots can offer specific advice and can sound like you’re talking with a human. Some AI apps can also help with reminders and productivity.

    Software engineer Bram de Buyser, said he created Goblin.tools with his neurodivergent friends in mind. Its most popular feature is the “magic to-do,” where a user can enter a task and the bot will spit out a to-do list. They can even break down items on the list into smaller tasks.

    “I’m not trying to build a cure,” he said, “but something that helps them out (for) two minutes out of the day that they would otherwise struggle with.”

    What kinds of problems could apps create?

    Husson University professor Russell Fulmer describes the research around AI and ADHD as “inconclusive.” While experts say they see how artificial intelligence could have a positive impact on the lives of people with anxiety and ADHD, Fulmer said, it may not work perfectly for everyone, like people of color with ADHD.

    He pointed to chatbot responses that have been racist and biased at times.

    Valese Jones, a publicist and founder of Sincerely Nicole Media, was diagnosed with ADHD as a child and uses AI bots to help with reading and responding to emails and proofreading public relations plans. But its responses don’t always capture who she really is.

    “I’m southern, so I talk like a southerner. There are cadences in my writing where you can kind of pick up on the fact that I’m southern, and that’s on purpose,” said Jones, who is Black. “It doesn’t pick up on Black women’s tone, and if you do put in like, ‘say it like African American,’ it automatically goes to talking like ‘Malibu’s Most Wanted.’”

    And de Buyser said while he sees a future where AI chatbots function more like a personal assistant that is “never tired, never sleeps,” it could also have privacy implications.

    “If you say, ‘Oh, I want an AI that gives me personal information and checks my calendar’ and all of that, you are giving that big company access to your emails, your calendar, personal correspondence, essentially your deepest, darkest secrets just so it can give you something useful back,” he warned.

    ___

    The Associated Press Health and Science Department receives support from the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

    [ad_2]

    Source link

  • Fauci faces partisan attacks at House hearing on COVID

    Fauci faces partisan attacks at House hearing on COVID

    [ad_1]

    WASHINGTON — Dr. Anthony Fauci, the top U.S. infectious disease expert until leaving the government in 2022, was back before Congress on Monday, calling “simply preposterous” Republican allegations that he tried to cover up origins of the COVID-19 pandemic.

    A GOP-led subcommittee has spent over a year probing the nation’s response to the pandemic and whether U.S.-funded research in China may have played any role in how it started — yet found no evidence linking Fauci to wrongdoing.

    He’d already been grilled behind closed doors, for 14 hours over two days in January. But Monday, Fauci testified voluntarily in public and on camera at a hearing that quickly deteriorated into partisan attacks.

    Republicans repeated unproven accusations against the longtime National Institutes of Health scientist while Democrats apologized for Congress besmirching his name and bemoaned a missed opportunity to prepare for the next scary outbreak.

    “He is not a comic book super villain,” said Rep. Jamie Raskin, D-Md., saying the Select Subcommittee on the Coronavirus Pandemic had failed to prove a list of damaging allegations.

    Fauci was the public face of the government’s early COVID-19 response under then-President Donald Trump and later as an adviser to President Joe Biden. A trusted voice to millions, he also was the target of partisan anger and choked up Monday as he recalled death threats and other harassment of himself and his family, threats he said still continue. Police later escorted hecklers out of the hearing room.

    The main issue: Many scientists believe the virus most likely emerged in nature and jumped from animals to people, probably at a wildlife market in Wuhan, the city in China where the outbreak began. There’s no new scientific information supporting that the virus might instead have leaked from a laboratory. A U.S. intelligence analysis says there’s insufficient evidence to prove either way — and a recent Associated Press investigation found the Chinese government froze critical efforts to trace the source of the virus in the first weeks of the outbreak.

    Fauci has long said publicly that he was open to both theories but that there’s more evidence supporting COVID-19’s natural origins, the way other deadly viruses including coronavirus cousins SARS and MERS jumped into people. It was a position he repeated Monday as Republican lawmakers questioned if he worked behind-the-scenes to squelch the lab-leak theory or even tried to influence intelligence agencies.

    “I have repeatedly stated that I have a completely open mind to either possibility and that if definitive evidence becomes available to validate or refute either theory, I will ready accept it,” Fauci said. He later invoked a fictional secret agent, decrying a conspiracy theory that “I was parachuting into the CIA like Jason Bourne and told the CIA that they should really not be talking about a lab leak.”

    Republicans also have accused Fauci of lying to Congress in denying that his agency funded “gain of function” research – the practicing of enhancing a virus in a lab to study its potential real-world impact – at a lab in Wuhan.

    NIH for years gave grants to a New York nonprofit called EcoHealth Alliance that used some of the funds to work with a Chinese lab studying coronaviruses commonly carried by bats. Last month, the government suspended EcoHealth’s federal funding, citing its failure to properly monitor some of those experiments.

    The definition of “gain of function” covers both general research and especially risky experiments to “enhance” the ability of potentially pandemic pathogens to spread or cause severe disease in humans. Fauci stressed he was using the risky experiment definition, saying “it would be molecularly impossible” for the bat viruses studied with EcoHealth’s funds to be turned into the virus that caused the pandemic.

    In an exchange with Rep. H. Morgan Griffith, R-Va., Fauci acknowledged that the lab leak is still an open question since it’s impossible to know if some other lab, not funded by NIH money, was doing risky research with coronaviruses.

    Fauci did face a new set of questions about the credibility of NIH’s National Institute of Allergy and Infectious Diseases, which he led for 38 years. Last month, the House panel revealed emails from an NIAID colleague about ways to evade public records laws, including by not discussing controversial pandemic issues in government email.

    Fauci denounced the actions of that colleague and insisted that “to the best of my knowledge I have never conducted official business via my personal email.”

    The pandemic’s origins weren’t the only hot topic. The House panel also blasted some public health measures taken to slow spread of the virus before COVID-19 vaccines, spurred by NIAID research, helped allow a return to normalcy. Ordering people to stay 6 feet apart meant many businesses, schools and churches couldn’t stay open, and subcommittee chairman Rep. Brad Wenstrup, R-Ohio, called it a “burdensome” and arbitrary rule, noting that in his prior closed-door testimony Fauci had acknowledged it wasn’t scientifically backed.

    Fauci responded Monday that the 6-feet distancing wasn’t his guideline but one created by the Centers for Disease Control and Prevention before scientists had learned that the new virus was airborne, not spread simply by droplets emitted a certain distance.


    The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

    Copyright 2024 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.

    [ad_2]

    By LAURAN NEERGAARD – AP Medical Writer

    Source link

  • Do men really sleep better than women? Experts explain

    Do men really sleep better than women? Experts explain

    [ad_1]

    Women and men sleep differently, so their sleep disorders shouldn’t be treated the same way, suggests new research that explores the biological sex characteristics of getting shut-eye.

    Men are more likely to have obstructive sleep apnea, while women are more likely to experience insomnia and report lower sleep quality. These are among the findings of a literature review published in April in the journal Sleep Medicine Reviews. The researchers hailed from Harvard University, Stanford University, and the University of Southampton in the U.K.

    This research is as much about precision medicine as it is sleep disparities between the sexes, says coauthor Renske Lok, PhD, a postdoctoral fellow at the Stanford Center for Sleep and Circadian Sciences.

    “We’re trying to move away from the one size fits all,” she tells Fortune. “[Medicine] needs to be more tailored.”

    Understanding how and why biological sex impacts various sleep disorders is a critical step toward individualized treatment. However, the long-standing lack of inclusion of women in biomedical and behavioral research is a hindrance. The National Institutes of Health didn’t require studies to account for sex as a biological variable until 2016.

    “The biggest finding is that we absolutely have to do better in including women in our research designs,” Lok says. “Historically, women have not been included as much as men, in part because it was always assumed results from men would translate automatically to women. And we’re starting to find out more and more that this is not the case.”

    Sex and circadian rhythm

    The mental, physical, and behavioral changes your body experiences in a 24-hour period are called circadian rhythms. Almost all your organs and tissues have their own rhythms, and together they form a kind of master biological clock that’s particularly sensitive to light and dark.

    At night, your brain produces more of the sleep hormone melatonin, which makes you feel tired. In one study reviewed by Lok and her colleagues, women secreted melatonin earlier in the evening than men. This aligns with other research showing men typically are later chronotypes; that is, they go to bed and wake up later than women. As such, men tend to have worse social jetlag, when their biological clock doesn’t align with the traditional timing of societal demands, like working a 9-5 job.

    Another study showed that core body temperature—which is highest before sleep and lowest a few hours before waking—also peaked earlier in women. Other research found that women’s circadian periods were about six minutes shorter than men’s: 24.09 hours compared to 24.19.

    “While this difference may be small, it is significant. The misalignment between the central body clock and the sleep/wake cycle is approximately five times larger in women than in men,” Lok said in a news release about her team’s work. “Imagine if someone’s watch was consistently running six minutes faster or slower. Over the course of days, weeks, and months, this difference can lead to a noticeable misalignment between the internal clock and external cues, such as light and darkness.

    “Disruptions in circadian rhythms have been linked to various health problems, including sleep disorders, mood disorders, and impaired cognitive function. Even minor differences in circadian periods can have significant implications for overall health and well-being.”

    Cognitive behavioral therapy is one option for getting your circadian rhythm on track—especially if your biological and social clocks don’t match up—says Alaina Tiani, PhD, a clinical psychologist at the Cleveland Clinic Sleep Disorders Center.

    “It differs patient to patient, but we have them take melatonin (supplements) earlier in the evening and then we have them use some bright-light exposure in the morning,” Tiani tells Fortune, referring to night owls who need to wake earlier. “Those two things help anchor their sleep window as they’re working on shifting things.”

    Man sleeping while wearing a CPAP mask for sleep apnea.
    Women and men sleep differently, so their sleep disorders shouldn’t be treated the same way, suggests new research that explores the biological sex characteristics of getting shut-eye.

    rdegrie—Getty Images

    Work-life stress may influence women’s insomnia

    You’ve likely experienced bouts of acute insomnia, stressful periods throughout your life when you’ve had difficulty falling asleep, staying asleep, or getting high-quality sleep. They may have lasted just days or as long as a few weeks. Chronic insomnia, though, is when you experience these sleep disruptions at least three times a week for more than three months, according to the National Heart, Lung, and Blood Institute. In addition, chronic insomnia can’t be explained by other health problems you may have.

    Insomnia is about 1.5 times more common in women, previous research has shown. Lok and her colleagues theorized this may be due to certain risk factors more prevalent in women, such as anxiety and depression.

    Dr. Eric Sklar is a neurologist and medical director of the Inova Sleep Disorders Program in northern Virginia. Insomnia is one of the most common sleep disorders he treats, and he was unsurprised by the review’s findings.

    “There is a high correlation with underlying psychiatric disorders and insomnia,” Sklar tells Fortune. “Some of the underlying societal stressors for men and women may be different.”

    Women still are often pigeonholed into the role of family caregiver, while also clawing their way up the career ladder, Sklar notes, not to mention fielding life’s other stressors. In addition, evening downtime is essential for healthy circadian rhythms and women sometimes have to fight harder for it, he says. And when so-called “revenge bedtime procrastination” involves screen time, women may be further disrupting their body clocks.

    By some objective measures, women sleep better than men, the review shows. Women have higher sleep efficiency, which refers to the percentage of time in bed actually spent sleeping. Women entered the dream-heavy rapid eye movement (REM) phase of sleep earlier, and spent about eight minutes longer in non-REM sleep. However, women self-reported poorer sleep quality than men.

    While new parents face a variety of sleep disruptions, Tiani tells Fortune a swath of her postpartum patients and women with young children report diminished sleep quality.

    “Almost like their brain was half-listening out for their children in the middle of the night, in case they needed something,” Tiani says. Patients who are caregivers in other capacities have reported the same thing, “that listening out in the night.”

    Why do men and women sleep differently?

    Women did catch a break with one common sleep disorder: obstructive sleep apnea, when the upper airway becomes blocked repeatedly during sleep. The disorder is almost three times as common in men, however, it’s only associated with an increased risk of heart failure in women, the review noted.

    “It is well known that men are at a higher risk,” Sklar tells Fortune, adding that biological sex is used in sleep apnea risk assessment. “Men tend to have larger necks, and neck size is also a risk factor.”

    Lok’s review also noted these sleep differences between the sexes, among others:

    One key factor remained inconsistent across the nearly 150 studies Lok and her colleagues analyzed: women’s menstrual phases. Menstruation correlates to numerous changes that impact sleep, such as elevated body temperature during the luteal phase of the cycle. What’s more, some research failed to consider subjects’ oral contraception usage, which may have skewed results.

    “It’s tricky because, for example, if somebody doesn’t use hormonal contraceptives, it means that you have to include women at the same menstrual phase,” Lok tells Fortune. “Otherwise, you get all kinds of variation due to changes in hormonal levels.”

    Having tackled some of the hurdles standing in her team’s way—namely, thin evidence of some biological sex differences—Lok is hopeful about future research.

    In some instances, “we’re not sure if there are any sex differences because, simply, nobody has ever looked at it,” Lok says. “At the same time, it’s a very encouraging article because it definitely identifies where the gaps are still present.”

    For more on biological sex and health:

    [ad_2]

    Lindsey Leake

    Source link

  • The American Academy of Stem Cell Physicians Recently Concluded Its  Seventh Scientific Session in Miami

    The American Academy of Stem Cell Physicians Recently Concluded Its Seventh Scientific Session in Miami

    [ad_1]

    Physicians and healthcare providers can attend the instructor course of TAI Chi now available at the conference. Dr AJ Farshchian held classes for Physicians.

    The American Academy of Stem Cell Physicians recently concluded its seventh scientific session at the Hyatt Hotel in Miami. The event served as a platform for innovation, collaboration, and education within the field of stem cell research and regenerative medicine.

    Dr. A.J. Farshchian led an engaging session on Tai Chi for arthritis, providing attendees with valuable insights into holistic approaches for managing arthritis, highlighting the importance of alternative therapies in enhancing patient well-being.

    On Sunday, the 11th of February, participants had the opportunity to undertake the Board Examination Part One, a critical step towards advancing their expertise and credentials within the Regenerative community.

    A moment of recognition and celebration was reserved for Dr. Frank Shallenberger, who was honored with the distinguished Scientist of the Year award. Dr. Shallenberger’s exceptional contributions and leadership in the realm of regenerative medicine research have been instrumental in shaping the future of regenerative medicine.

    Furthermore, the event witnessed the recognition of five outstanding physicians who were awarded the status of Diplomates of the American Academy of Stem Cell Physicians, acknowledging their commitment to excellence and expertise in the field.

    The seventh scientific session of the American Academy of Stem Cell Physicians was an important event fostering meaningful discussions, knowledge sharing, and professional growth among attendees.

    The Academy looks forward to building on this success and continuing to drive innovation and excellence in the dynamic field of regenerative medicine.

    For more information about the American Academy of Stem Cell Physicians and upcoming events, please visit https://www.aascpconference.miami (https://www.aascpconference.miami).

    Contact:
    Claudia Salazar
    Executive Coordinator
    American Academy of Stem Physicians
    claudia@genorthix.com

    Source: American Academy of Stem Cell Physicians

    [ad_2]

    Source link

  • Science sleuths are using technology to find fakery and plagiarism in published research

    Science sleuths are using technology to find fakery and plagiarism in published research

    [ad_1]

    Allegations of research fakery at a leading cancer center have turned a spotlight on scientific integrity and the amateur sleuths uncovering image manipulation in published research.

    Dana-Farber Cancer Institute, a Harvard Medical School affiliate, announced Jan. 22 it’s requesting retractions and corrections of scientific papers after a British blogger flagged problems in early January.

    The blogger, 32-year-old Sholto David, of Pontypridd, Wales, is a scientist-sleuth who detects cut-and-paste image manipulation in published scientific papers.

    He’s not the only hobbyist poking through pixels. Other champions of scientific integrity are keeping researchers and science journals on their toes. They use special software, oversize computer monitors and their eagle eyes to find flipped, duplicated and stretched images, along with potential plagiarism.

    A look at the situation at Dana-Farber and the sleuths hunting sloppy errors and outright fabrications:

    In a Jan. 2 blog post, Sholto David presented suspicious images from more than 30 published papers by four Dana-Farber scientists, including CEO Laurie Glimcher and COO William Hahn.

    Many images appeared to have duplicated segments that would make the scientists’ results look stronger. The papers under scrutiny involve lab research on the workings of cells. One involved samples from bone marrow from human volunteers.

    The blog post included problems spotted by David and others previously exposed by sleuths on PubPeer, a site that allows anonymous comments on scientific papers.

    Student journalists at The Harvard Crimson covered the story on Jan. 12, followed by reports in other news media. Sharpening the attention was the recent plagiarism investigation involving former Harvard president Claudine Gay, who resigned early this year.

    Dana-Farber said it already had been looking into some of the problems before the blog post. By Jan. 22, the institution said it was in the process of requesting six retractions of published research and that another 31 papers warranted corrections.

    Retractions are serious. When a journal retracts an article that usually means the research is so severely flawed that the findings are no longer reliable.

    Dr. Barrett Rollins, research integrity officer at Dana-Farber, said in a statement: “Following the usual practice at Dana-Farber to review any potential data error and make corrections when warranted, the institution and its scientists already have taken prompt and decisive action in 97 percent of the cases that had been flagged by blogger Sholto David.”

    California microbiologist Elisabeth Bik, 57, has been sleuthing for a decade. Based on her work, scientific journals have retracted 1,133 articles, corrected 1,017 others and printed 153 expressions of concern, according to a spreadsheet where she tracks what happens after she reports problems.

    She has found doctored images of bacteria, cell cultures and western blots, a lab technique for detecting proteins.

    “Science should be about finding the truth,” Bik told The Associated Press. She published an analysis in the American Society for Microbiology in 2016: Of more than 20,000 peer-reviewed papers, nearly 4% had image problems, about half where the manipulation seemed intentional.

    Bik’s work brings donations from Patreon subscribers of about $2,300 per month and occasional honoraria from speaking engagements. David told AP his Patreon income recently picked up to $216 per month.

    Technology has made it easier to root out image manipulation and plagiarism, said New York University science educator Ivan Oransky, co-founder of the Retraction Watch blog. The sleuths download scientific papers and use software tools to help find problems.

    Others doing the investigative work remain anonymous and post their findings under pseudonyms. Together, they have “changed the equation” in scientific publication, Oransky said.

    “They want science to be and do better,” Oransky said. “And they are frustrated by how uninterested most people in academia — and certainly in publishing — are in correcting the record.” They’re also concerned about the erosion of public trust in science.

    Bik said some mistakes could be sloppy errors where images were mislabeled or “somebody just grabbed the wrong photo.”

    But some images are obviously altered with sections duplicated or rotated or flipped. Scientists building their careers or seeking tenure face pressure to get published. Some may intentionally falsify data, knowing that the process of peer review — when a journal sends a manuscript to experts for comments — is unlikely to catch fakery.

    “At the end of the day, the motivation is to get published,” Oransky said. “When the images don’t match the story you’re trying to tell, you beautify them.”

    Scientific journals investigate errors brought to their attention but usually keep their processes confidential until they take action with a retraction or correction.

    Some journals told the AP they are aware of the concerns raised by David’s blog post and were looking into the matter.

    ___

    The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

    [ad_2]

    Source link

  • Aide to Lloyd Austin asked ambulance to arrive quietly to defense secretary's home, 911 call shows

    Aide to Lloyd Austin asked ambulance to arrive quietly to defense secretary's home, 911 call shows

    [ad_1]

    An aide to Defense Secretary Lloyd Austin asked first responders to avoid using lights and sirens in requesting an ambulance be sent to Austin’s northern Virginia home after he had complications from surgery for prostate cancer that he had kept secret from senior Biden administration leaders and staff.

    Austin was hospitalized Jan. 1 and admitted to intensive care after developing an infection a week after undergoing surgery. He was released from Walter Reed National Military Medical Center on Monday.

    On the Jan. 1 call to the Fairfax County Department of Public Safety, a man who identified himself as a government employee described Austin as alert. The identity of Austin and the caller were redacted from a copy of the 911 audio, which was obtained by The Associated Press under the Freedom of Information Act. The caller named the street on which Austin lives.

    In the four-minute call, the reason for needing the ambulance also was redacted. The caller said Austin was not having chest pains.

    “Can I ask, like, can the ambulance not show up with lights and sirens? Um, we’re trying to remain a little subtle,” the aide said, according to the recording.

    A dispatcher responded that the ambulance would comply once it got near the home.

    “Usually when they turn into a residential neighborhood, they’ll turn them off,” the dispatcher said, adding that emergency sirens and lights are required by law on major roads when ambulances are responding to a call.

    Austin was located on the ground floor of the residence, said the aide, who indicated he would be waiting outside for the ambulance.

    The caller asked how long it would take to get to the home. The dispatcher said it depended on traffic and road conditions and said first responders would be arriving from the closest available station.

    Details of the 911 audio file from the Fairfax County Public Safety Department were first reported by The Daily Beast.

    As he recovers, Austin will be working from home. His doctors said he “progressed well throughout his stay and his strength is rebounding.” They said in a statement the cancer was treated early and his prognosis is “excellent.”

    Austin, 70, was admitted to Walter Reed National Military Medical Center on Dec. 22 and underwent surgery to treat the cancer, which was detected earlier in the month during a routine screening.

    Dr. John Maddox, the trauma medical director, and Dr. Gregory Chesnut, the director of the Center for Prostate Disease Research at Walter Reed, said that during Austin’s hospitalization he underwent medical tests and was treated for lingering leg pain. They said he has physical therapy to do but there are no plans for further cancer treatment other than regular checks.

    President Joe Biden and senior administration officials were not told about Austin’s hospitalization until Jan. 4, and Austin kept the cancer diagnosis secret until Jan. 9. Biden has said Austin’s failure to tell him about the hospitalization was a lapse in judgment, but the Democratic president insists he still has confidence in his Pentagon chief.

    During Austin’s time at Walter Reed, the U.S. launched a series of military strikes late last week on the Iranian-backed Houthis in Yemen, targeting dozens of locations linked to their campaign of assaults on commercial shipping in the Red Sea. Working from his hospital bed, Austin juggled calls with senior military leaders, including Gen. Erik Kurilla, head of U.S. Central Command, and White House meetings to review, order and ultimately watch the strikes unfold over secure video.

    The lack of transparency about Austin’s hospitalization, however, has triggered administration and Defense Department reviews on the procedures for notifying the White House and others if a Cabinet member must transfer decision-making authorities to a deputy, as Austin did during his initial surgery and a portion of his latest hospital stay. And the White House chief of staff ordered Cabinet members to notify his office if they ever can’t perform their duties.

    Austin’s secrecy also drew criticism from Congress members on both sides of the political aisle, and Rep. Mike Rogers, an Alabama Republican who is chairman of the House Armed Services Committee, said he has opened a formal inquiry into the matter. Others openly called for Austin to resign, but the White House has said the Pentagon chief’s job is safe.

    It is still unclear when Austin will return to his office in the Pentagon or how his cancer treatment will affect his job, travel and other public engagements going forward. Deputy Defense Secretary Kathleen Hicks has been taking on some of his day-to-day duties as he recovers.

    ___

    Follow the AP’s coverage of Defense Secretary Lloyd Austin at https://apnews.com/hub/lloyd-austin.

    [ad_2]

    Source link

  • The Most Mysterious Cells in Our Bodies Don’t Belong to Us

    The Most Mysterious Cells in Our Bodies Don’t Belong to Us

    [ad_1]

    Some 24 years ago, Diana Bianchi peered into a microscope at a piece of human thyroid and saw something that instantly gave her goosebumps. The sample had come from a woman who was chromosomally XX. But through the lens, Bianchi saw the unmistakable glimmer of Y chromosomes—dozens and dozens of them. “Clearly,” Bianchi told me, “part of her thyroid was entirely male.”

    The reason, Bianchi suspected, was pregnancy. Years ago, the patient had carried a male embryo, whose cells had at some point wandered out of the womb. They’d ended up in his mother’s thyroid—and, almost certainly, a bunch of other organs too—and taken on the identities and functions of the female cells that surrounded them so they could work in synchrony. Bianchi, now the director of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, was astonished: “Her thyroid had been entirely remodeled by her son’s cells,” she said.

    The woman’s case wasn’t a one-off. Just about every time an embryo implants and begins to grow, it dispatches bits of itself into the body housing it. The depositions begin at least as early as four or five weeks into gestation. And they settle into just about every sliver of our anatomy where scientists have checked—the heart, the lungs, the breast, the colon, the kidney, the liver, the brain. From there, the cells might linger, grow, and divide for decades, or even, as many scientists suspect, for a lifetime, assimilating into the person that conceived them. They can almost be thought of as evolution’s original organ transplant, J. Lee Nelson, of the Fred Hutchinson Cancer Center in Seattle, told me. Microchimerism may be the most common way in which genetically identical cells mature and develop inside two bodies at once.

    These cross-generational transfers are bidirectional. As fetal cells cross the placenta into maternal tissues, a small number of maternal cells migrate into fetal tissues, where they can persist into adulthood. Genetic swaps, then, might occur several times throughout a life. Some researchers believe that people may be miniature mosaics of many of their relatives, via chains of pregnancy: their older siblings, perhaps, or their maternal grandmother, or any aunts and uncles their grandmother might have conceived before their mother was born. “It’s like you carry your entire family inside of you,” Francisco Úbeda de Torres, an evolutionary biologist at the Royal Holloway University of London, told me.

    All of that makes microchimerism—named in homage to the part-lion, part-goat, part-dragon chimera of Greek myth—more common than pregnancy itself. It’s thought to affect every person who has carried an embryo, even if briefly, and anyone who has ever inhabited a womb. Other mammals—mice, cows, dogs, our fellow primates—seem to haul around these cellular heirlooms too. But borrowed cells don’t always show up in the same spots, or in the same numbers. In many cases, microchimeric cells are thought to be present at concentrations on the order of one in 1 million—levels that, “for a lot of biological assays, is approaching or at the limit of detection,” Sing Sing Way, an immunologist and a pediatrician at Cincinnati Children’s Hospital, told me.

    Some scientists have argued that cells so sparse and inconsistent couldn’t possibly have meaningful effects. Even among microchimerism researchers, hypotheses about what these cells do—if anything at all—remain “highly controversial,” Way said. But many experts contend that microchimeric cells aren’t just passive passengers, adrift in someone else’s genomic sea. They are genetically distinct entities in a foreign residence, with their own evolutionary motivations that may clash with their landlord’s. And they might hold sway over many aspects of health: our susceptibility to infectious or autoimmune disease, the success of pregnancies, maybe even behavior. If these cells turn out to be as important as some scientists believe they are, they might be one of the most underappreciated architects of human life.

    Already, researchers have uncovered hints of what these wandering cells are up to. Way’s studies in mice, for instance, suggest that the microchimerism that babies inherit during gestation might help fine-tune their immune system, steeling the newborn body against viral infections; as the rodents age, their mother’s cells may aid in bringing their own pregnancies to term, by helping them see the fetus—made up of half-foreign DNA—as benign, rather than an unfamiliar threat.

    Similarly, inherited microchimerism might help explain why some studies have found that people are better at accepting organs from their mother than from their father, says William Burlingham, a transplant specialist at the University of Wisconsin at Madison. In the early ’90s, Burlingham treated a kidney-transplant patient who had abruptly stopped taking his immunosuppressive medications—a move that should have prompted his body’s rejection of the new organ. But “he was doing fine,” Burlingham told me. The patient’s kidney had come from his mother, whose cells were still circulating in his blood and skin; when his body encountered the transplanted tissues, it saw the newcomers as more of the same.

    Even fetal cells that meander into mothers during pregnancy might buoy the baby’s health. David Haig, an evolutionary biologist at Harvard, thinks that these cells may position themselves to optimally extract resources from Mom: in the brain, to command more attention; in the breast, to stimulate more milk production; in the thyroid, to coax more body heat. The cells, he told me, might also fiddle with a mother’s fertility, extending the interval between births to give the baby more uninterrupted care. Fetal delegates could then serve as informants for future offspring that inhabit the same womb, Úbeda de Torres told me. If later fetuses don’t detect much relatedness between themselves and their older siblings, he said, they might become greedier when siphoning nutrients from their mother’s body, rather than leaving extra behind for future siblings whose paternity may also differ from theirs.

    The perks of microchimerism for mothers have been tougher to pin down. One likely possibility is that the more thoroughly embryonic cells infiltrate the mother’s body, the better she might be able to tolerate her fetus’s tissue, reducing her chances of miscarriage or a high-risk birth. “I really think it’s a baby’s insurance policy on the mom,” Amy Boddy, a biological anthropologist at UC Santa Barbara, told me. “Like, ‘Hey, don’t attack.’” After delivery, the cells that stick around in the mother’s body may ease future pregnancies too (at least those by the same father). Pregnancy complications such as preeclampsia become rarer the more times someone conceives with the same partner. And when mothers send cellular envoys into their babies, they might be able to cut Mom a break by upping a child’s sleepiness, or curbing their fussiness.

    Microchimerism may not always be kind to moms. Nelson and others have found that, long-term, women with more fetal cells are also more likely to develop certain kinds of autoimmune disease, perhaps because their children’s cells are mistakenly reassessed by certain postpartum bodies as unwanted invaders. Nelson’s former postdoctoral fellow Nathalie Lambert, now at the French National Institute of Health and Medical Research, has found evidence in mouse experiments that fetal microchimeric cells may also produce antibodies that can goad attacks on maternal cells, Lambert told me. But the situation is also more complicated than that. “I don’t think they’re bad actors,” Nelson said of the interloping fetal cells. She and her colleagues have also found that fetal cells might sometimes protect against autoimmunity, leading a few conditions, such as rheumatoid arthritis, to actually abate during and shortly after pregnancy.

    In other contexts, too, fetal cells might offer both help and harm to the mother, or neither at all. Fetally derived microchimeric cells have been spotted voyaging into the cardiac tissues of mice who have experienced mid-pregnancy heart attacks, settling the pancreases of newly diabetic mouse moms, and lurking inside human tumors and C-section scars. But scientists aren’t sure whether the foreign cells are causing damage, repairing it, or simply bystanders, discovered in these spots by coincidence.

    These questions are so difficult to answer, Way told me, because microchimeric cells are so challenging to study. They might be in all of us, but they’re still rare, and frequently hidden in tough-to-access internal tissues. Researchers can’t yet say whether the cells actively deploy to predetermined sites or are pulled into specific organs by maternal cells—or just follow the natural flow of blood like river sediments. There’s also no consensus on how much microchimerism a body can tolerate. In a vacuum of evidence, even microchimerism researchers are steeling themselves for a letdown. “A very large part of me is prepared to think that most if not all microchimerism is completely benign,” Melissa Wilson, a computational evolutionary biologist at Arizona State University, told me.

    But if microchimeric cells do have a role to play in autoimmunity or reproductive success, the potential for therapies could be huge. One option, Burlingham told me, might be to infuse organ-transplant patients with cells from their mother, which could, like tiny ambassadors, coax the body into accepting any new tissue. Microchimerism-inspired therapies could help ease the burdens of high-risk pregnancies, Boddy told me, many of which seem to be fueled by the maternal body mounting an inappropriately aggressive immune response. They might also improve the experience of surrogates, who are more likely to experience pregnancy complications such as high blood pressure, preterm birth, and gestational diabetes. The cells’ stem-esque properties could even help researchers design better treatments for genetic diseases in utero; one research group, at UC San Francisco, is pursuing this idea for the blood disorder alpha thalassemia.

    Before those visions can be enacted, some questions need to be resolved. Researchers have unearthed evidence that microchimeric cells from different sources might sometimes compete with, or even displace one another, in bids for dominance. If the same dynamic plays out with future therapies, doctors may need to be careful about which cells they introduce to people and when, or risk losing the precious cargo they infuse. And, perhaps most fundamental, scientists can’t yet say how many microchimeric cells are necessary to exert influence over a specific person’s health—a threshold that will likely determine just how practical these theoretical treatments might be, Kristine Chua, a biological anthropologist at UCSB, told me.

    Even amid these uncertainties, the experts I spoke with stand by microchimerism’s likely importance: The cells are so persistent, so ubiquitous, so evolutionarily ancient, Boddy told me, that they must have an effect. The simple fact that they’re allowed to stick around for decades, while they grow and develop and change, could have a lot to teach us about immunity—and our understanding of ourselves. “In my mind, it does alter my concept of who I am,” Bianchi, who herself has given birth to a son, told me. Although he’s since grown up, she’s never without him, nor he without her.

    [ad_2]

    Katherine J. Wu

    Source link

  • No antibiotics worked, so this woman turned to a natural enemy of bacteria to save her husband's life | CNN

    No antibiotics worked, so this woman turned to a natural enemy of bacteria to save her husband's life | CNN

    [ad_1]



    CNN
     — 

    In February 2016, infectious disease epidemiologist Steffanie Strathdee was holding her dying husband’s hand, watching him lose an exhausting fight against a deadly superbug infection.

    After months of ups and downs, doctors had just told her that her husband, Tom Patterson, was too racked with bacteria to live.

    “I told him, ‘Honey, we’re running out of time. I need to know if you want to live. I don’t even know if you can hear me, but if you can hear me and you want to live, please squeeze my hand.’

    “All of a sudden, he squeezed really hard. And I thought, ‘Oh, great!’ And then I’m thinking, ‘Oh, crap! What am I going to do?’”

    What she accomplished next could easily be called miraculous. First, Strathdee found an obscure treatment that offered a glimmer of hope — fighting superbugs with phages, viruses created by nature to eat bacteria.

    Then she convinced phage scientists around the country to hunt and peck through molecular haystacks of sewage, bogs, ponds, the bilge of boats and other prime breeding grounds for bacteria and their viral opponents. The impossible goal: quickly find the few, exquisitely unique phages capable of fighting a specific strain of antibiotic-resistant bacteria literally eating her husband alive.

    Next, the US Food and Drug Administration had to greenlight this unproven cocktail of hope, and scientists had to purify the mixture so that it wouldn’t be deadly.

    Yet just three weeks later, Strathdee watched doctors intravenously inject the mixture into her husband’s body — and save his life.

    Their story is one of unrelenting perseverance and unbelievable good fortune. It’s a glowing tribute to the immense kindness of strangers. And it’s a story that just might save countless lives from the growing threat of antibiotic-resistant superbugs — maybe even your own.

    “It’s estimated that by 2050, 10 million people per year — that’s one person every three seconds — is going to be dying from a superbug infection,” Strathdee told an audience at Life Itself, a 2022 health and wellness event presented in partnership with CNN.

    “I’m here to tell you that the enemy of my enemy can be my friend. Viruses can be medicine.”

    sanjay pkg vpx

    How this ‘perfect predator’ saved his life after nine months in the hospital

    During a Thanksgiving cruise on the Nile in 2015, Patterson was suddenly felled by severe stomach cramps. When a clinic in Egypt failed to help his worsening symptoms, Patterson was flown to Germany, where doctors discovered a grapefruit-size abdominal abscess filled with Acinetobacter baumannii, a virulent bacterium resistant to nearly all antibiotics.

    Found in the sands of the Middle East, the bacteria were blown into the wounds of American troops hit by roadside bombs during the Iraq War, earning the pathogen the nickname “Iraqibacter.”

    “Veterans would get shrapnel in their legs and bodies from IED explosions and were medevaced home to convalesce,” Strathdee told CNN, referring to improvised explosive devices. “Unfortunately, they brought their superbug with them. Sadly, many of them survived the bomb blasts but died from this deadly bacterium.”

    Today, Acinetobacter baumannii tops the World Health Organization’s list of dangerous pathogens for which new antibiotics are critically needed.

    “It’s something of a bacterial kleptomaniac. It’s really good at stealing antimicrobial resistance genes from other bacteria,” Strathdee said. “I started to realize that my husband was a lot sicker than I thought and that modern medicine had run out of antibiotics to treat him.”

    With the bacteria growing unchecked inside him, Patterson was soon medevaced to the couple’s hometown of San Diego, where he was a professor of psychiatry and Strathdee was the associate dean of global health sciences at the University of California, San Diego.

    “Tom was on a roller coaster — he’d get better for a few days, and then there would be a deterioration, and he would be very ill,” said Dr. Robert “Chip” Schooley, a leading infectious disease specialist at UC San Diego who was a longtime friend and colleague. As weeks turned into months, “Tom began developing multi-organ failure. He was sick enough that we could lose him any day.”

    Patterson's body was systemically infected with a virulent drug-resistant bacteria that also infected troops in the Iraq War, earning the pathogen the nickname

    After that reassuring hand squeeze from her husband, Strathdee sprang into action. Scouring the internet, she had already stumbled across a study by a Tbilisi, Georgia, researcher on the use of phages for treatment of drug-resistant bacteria.

    A phone call later, Strathdee discovered phage treatment was well established in former Soviet bloc countries but had been discounted long ago as “fringe science” in the West.

    “Phages are everywhere. There’s 10 million trillion trillion — that’s 10 to the power of 31 — phages that are thought to be on the planet,” Strathdee said. “They’re in soil, they’re in water, in our oceans and in our bodies, where they are the gatekeepers that keep our bacterial numbers in check. But you have to find the right phage to kill the bacterium that is causing the trouble.”

    Buoyed by her newfound knowledge, Strathdee began reaching out to scientists who worked with phages: “I wrote cold emails to total strangers, begging them for help,” she said at Life Itself.

    One stranger who quickly answered was Texas A&M University biochemist Ryland Young. He’d been working with phages for over 45 years.

    “You know the word persuasive? There’s nobody as persuasive as Steffanie,” said Young, a professor of biochemistry and biophysics who runs the lab at the university’s Center for Phage Technology. “We just dropped everything. No exaggeration, people were literally working 24/7, screening 100 different environmental samples to find just a couple of new phages.”

    While the Texas lab burned the midnight oil, Schooley tried to obtain FDA approval for the injection of the phage cocktail into Patterson. Because phage therapy has not undergone clinical trials in the United States, each case of “compassionate use” required a good deal of documentation. It’s a process that can consume precious time.

    But the woman who answered the phone at the FDA said, “‘No problem. This is what you need, and we can arrange that,’” Schooley recalled. “And then she tells me she has friends in the Navy that might be able to find some phages for us as well.”

    In fact, the US Naval Medical Research Center had banks of phages gathered from seaports around the world. Scientists there began to hunt for a match, “and it wasn’t long before they found a few phages that appeared to be active against the bacterium,” Strathdee said.

    Dr. Robert

    Back in Texas, Young and his team had also gotten lucky. They found four promising phages that ravaged Patterson’s antibiotic-resistant bacteria in a test tube. Now the hard part began — figuring out how to separate the victorious phages from the soup of bacterial toxins left behind.

    “You put one virus particle into a culture, you go home for lunch, and if you’re lucky, you come back to a big shaking, liquid mess of dead bacteria parts among billions and billions of the virus,” Young said. “You want to inject those virus particles into the human bloodstream, but you’re starting with bacterial goo that’s just horrible. You would not want that injected into your body.”

    Purifying phage to be given intravenously was a process that no one had yet perfected in the US, Schooley said, “but both the Navy and Texas A&M got busy, and using different approaches figured out how to clean the phages to the point they could be given safely.”

    More hurdles: Legal staff at Texas A&M expressed concern about future lawsuits. “I remember the lawyer saying to me, ‘Let me see if I get this straight. You want to send unapproved viruses from this lab to be injected into a person who will probably die.’ And I said, “Yeah, that’s about it,’” Young said.

    “But Stephanie literally had speed dial numbers for the chancellor and all the people involved in human experimentation at UC San Diego. After she calls them, they basically called their counterparts at A&M, and suddenly they all began to work together,” Young added.

    “It was like the parting of the Red Sea — all the paperwork and hesitation disappeared.”

    The purified cocktail from Young’s lab was the first to arrive in San Diego. Strathdee watched as doctors injected the Texas phages into the pus-filled abscesses in Patterson’s abdomen before settling down for the agonizing wait.

    “We started with the abscesses because we didn’t know what would happen, and we didn’t want to kill him,” Schooley said. “We didn’t see any negative side effects; in fact, Tom seemed to be stabilizing a bit, so we continued the therapy every two hours.”

    Two days later, the Navy cocktail arrived. Those phages were injected into Patterson’s bloodstream to tackle the bacteria that had spread to the rest of his body.

    “We believe Tom was the first person to receive intravenous phage therapy to treat a systemic superbug infection in the US,” Strathdee told CNN.

    “And three days later, Tom lifted his head off the pillow out of a deep coma and kissed his daughter’s hand. It was just miraculous.”

    Patterson awoke from a coma after receiving an intravenous dose of phages tailored to his bacteria.

    Today, nearly eight years later, Patterson is happily retired, walking 3 miles a day and gardening. But the long illness took its toll: He was diagnosed with diabetes and is now insulin dependent, with mild heart damage and gastrointestinal issues that affect his diet.

    “He isn’t back surfing again, because he can’t feel the bottoms of his feet, and he did get Covid-19 in April that landed him in the hospital because the bottoms of his lungs are essentially dead,” Strathdee said.

    “As soon as the infection hit his lungs he couldn’t breathe and I had to rush him to the hospital, so that was scary,” she said. “He remains high risk for Covid but we’re not letting that hold us hostage at home. He says, ‘I want to go back to having as normal life as fast as possible.’”

    To prove it, the couple are again traveling the world — they recently returned from a 12-day trip to Argentina.

    “We traveled with a friend who is an infectious disease doctor, which gave me peace of mind to know that if anything went sideways, we’d have an expert at hand,” Strathdee said.

    “I guess I’m a bit of a helicopter wife in that sense. Still, we’ve traveled to Costa Rica a couple of times, we’ve been to Africa, and we’re planning to go to Chile in January.”

    Patterson’s case was published in the journal Antimicrobial Agents and Chemotherapy in 2017, jump-starting new scientific interest in phage therapy.

    “There’s been an explosion of clinical trials that are going on now in phage (science) around the world and there’s phage programs in Canada, the UK, Australia, Belgium, Sweden, Switzerland, India and China has a new one, so it’s really catching on,” Strathdee told CNN.

    Some of the work is focused on the interplay between phages and antibiotics — as bacteria battle phages they often shed their outer shell to keep the enemy from docking and gaining access for the kill. When that happens, the bacteria may be suddenly vulnerable to antibiotics again.

    “We don’t think phages are ever going to entirely replace antibiotics, but they will be a good adjunct to antibiotics. And in fact, they can even make antibiotics work better,” Strathdee said.

    In San Diego, Strathdee and Schooley opened the Center for Innovative Phage Applications and Therapeutics, or IPATH, in 2018, where they treat or counsel patients suffering from multidrug-resistant infections. The center’s success rate is high, with 82% of patients undergoing phage therapy experiencing a clinically successful outcome, according to its website.

    Schooley is running a clinical trial using phages to treat patients with cystic fibrosis who constantly battle Pseudomonas aeruginosa, a drug-resistant bacteria that was also responsible for the recent illness and deaths connected to contaminated eye drops manufactured in India.

    And a memoir the couple published in 2019 — “The Perfect Predator: A Scientist’s Race to Save Her Husband From a Deadly Superbug” — is also spreading the word about these “perfect predators” to what may soon be the next generation of phage hunters.

    VS Phages Sanjay Steffanie

    How naturally occurring viruses could help treat superbug infections

    “I am getting increasingly contacted by students, some as young as 12,” Strathdee said. “There’s a girl in San Francisco who begged her mother to read this book and now she’s doing a science project on phage-antibiotic synergy, and she’s in eighth grade. That thrills me.”

    Strathdee is quick to acknowledge the many people who helped save her husband’s life. But those who were along for the ride told CNN that she and Patterson made the difference.

    “I think it was a historical accident that could have only happened to Steffanie and Tom,” Young said. “They were at UC San Diego, which is one of the premier universities in the country. They worked with a brilliant infectious disease doctor who said, ‘Yes,’ to phage therapy when most physicians would’ve said, ‘Hell, no, I won’t do that.’

    “And then there is Steffanie’s passion and energy — it’s hard to explain until she’s focused it on you. It was like a spiderweb; she was in the middle and pulled on strings,” Young added. “It was just meant to be because of her, I think.”

    [ad_2]

    Source link

  • Expert Panel Provides Updated Data for Epilepsy and Pregnancy

    Expert Panel Provides Updated Data for Epilepsy and Pregnancy

    [ad_1]

    The Epilepsy & Pregnancy Medical Consortium (EPMC), an expert panel of leading epileptologists and OB-GYN researchers/practitioners, announced updated best practice recommendations for people with epilepsy who are considering pregnancy, are pregnant, or are postpartum. These new best practices are based on the findings of the groundbreaking study Maternal Outcomes and Neurodevelopment Effects of Antiepileptic Drugs (MONEAD) and its predecessor study Fetal Antiepileptic Drug Exposure and Cognitive Outcomes at Age 6 Years (NEAD study).

    MONEAD followed 565 women, including pregnant women with epilepsy, non-pregnant women with epilepsy, and pregnant women without epilepsy to explore the impact of various anti-seizure medications on seizure frequency, maternal outcomes, breastfeeding, and child outcomes (such as verbal and intellectual abilities) through six years of age.

    Based on the results of this study, the EPMC asserts that with proper planning and therapeutic monitoring of pregnancy-suitable anti-seizure medications, such as lamotrigine and levetiracetam monotherapy, people with epilepsy can have safe, healthy pregnancies and healthy babies. 

    The data also countered the misconception that it is not safe for people who take anti-seizure medications to breastfeed their babies. Neurodevelopmental outcomes at age six were better in children exposed to anti-seizure medications in utero who were breastfed compared to those who were not breastfed.

    Dr. Page Pennell, M.D., F.A.E.S., is the department chair of neurology at the University of Pittsburgh School of Medicine and co-investigator of the MONEAD study.

    “There’s a lot of information out there about the danger of anti-seizure medications. But we know at this time that some medications are very safe to use during the childbearing years. But with that in mind it’s important that when it is time to have children we have everything in place, and then we have a planned pregnancy,” said Dr. Pennell.

    Dr. Elizabeth Gerard, M.D., is an epileptologist and professor of neurology at Northwestern University.

    “We have a research study that suggests that the children who were breastfed [from a parent who was taking] anti-seizure medicines had higher IQs than those [children] who were not breastfed. So we emphasize that for most of our drugs, we have strong evidence that there is a low risk of breastfeeding or almost no documented risk. For those [anti-seizure medications for which] we don’t have strong evidence, it is more of a theoretical risk,” said Dr. Gerard.

    Because family planning can have such a positive impact on pregnancy outcomes for epilepsy patients, The EPMC also provides best-practice recommendations for contraceptive use and other considerations for patients during their childbearing years. Some anti-seizure medications can interfere with certain hormonal contraceptives, rendering them less effective. 

    The EPMC’s mission is to reach as many patients and clinicians as possible so they can use this new data to guide their healthcare decisions and understand the best treatment options. For information regarding the MONEAD study, care recommendations, downloadable tools, resources, and more, visit their website: epilepsypregnancy.com.

    Source: Epilepsy & Pregnancy Medical Consortium (EPMC)

    [ad_2]

    Source link

  • Coal power, traffic, waste burning a toxic smog cocktail in Indonesia’s Jakarta

    Coal power, traffic, waste burning a toxic smog cocktail in Indonesia’s Jakarta

    [ad_1]

    JAKARTA, Indonesia — Against the backdrop of smokestacks from a nearby coal power plant, the sky above Edy Suryana’s village stays grey for months at a time, while ashes and the stench of smoke hang in the air.

    Suryana has spent more than three decades living in the shadow of the power plant in northern Java, just 60 miles from Jakarta, Indonesia’s most populous city. She and other villagers have watched as their loved ones suffered from coughing fits, itchy skin and other health problems that many believe are partly because of the ever-present smog.

    Pollution is causing a rise in respiratory illnesses and deaths in northern Java, including Jakarta, experts say. Smog in the metropolis of 11.2 million people comes from a combination of the coal-fired plants, vehicle and motorcycle exhaust, trash burning and industries, and many in the city are demanding that the government take action.

    Emissions from coal-fired power plants contribute to greenhouse gases that rise into the atmosphere and help heat the planet, a key focus of the United Nations climate conference, or COP28, which begins next week in Dubai.

    Countries like Indonesia are struggling to balance rising demand to power industrialization with the need to cut carbon emissions and protect public health.

    In 2010 Suryana watched as his sister-in-law died from lung problems. In 2019, the dirty air seemed to worsen his daughter’s bout of tuberculosis.

    “We’ve clearly suffered an impact,” he told The Associated Press.

    Data gathered by IQAir, a Swiss air technology company, regularly ranks Jakarta as one of the most polluted cities in the world. Blue skies are a rare sight and the air often smells like petrol or heavy smoke. Normally healthy residents complain of itchy eyes and sore throats on days when pollution levels soar past levels considered safe by the World Health Organization and Indonesian government.

    Air pollution potentially contributed to more than 10,000 deaths and 5,000 hospitalizations in Jakarta in 2019, according to research conducted by Vital Strategies, a global health public health nongovernmental organization that is headquartered in New York.

    Pollution levels get and stay so high that it’s not safe for people to do outdoor activities without risking short and long-term damage to their health, said Ginanjar Syuhada, a health analyst at Vital Strategies.

    But not everyone is able to stay inside.

    Misnar, a street vendor who spends his days working outdoors — and like many Indonesians only uses one name — went to the hospital on September and spent days in a special air chamber to treat his pneumonia, which was worsened by routinely working outdoors in the polluted air, said Misnar’s eldest daughter, Siti Nurzanah.

    His doctor recommended that Misnar stay home after he left the hospital. But he makes his living selling items on the street. So his only option is to rely on face masks to help filter the dirty air he breathes.

    “I want my father to stay at home. My father is old, 63, the air is bad with his health condition,” Nurzanah said.

    Acute respiratory infections and pneumonia cases have been increasing, according to a spokesperson from Indonesia’s Ministry of Health, who also recognized that Jakarta’s air pollution has exceeded WHO safe limits.

    Data from the Jakarta Health Agency show that the number of residents treated for pneumonia from January to August was more than double the same period the year before, at 9,192 cases.

    The number of patients visiting Jakarta’s Persahabatan Hospital, a national respiratory referral hospital, with acute respiratory infections and pneumonia from January to August likewise doubled.

    The heavy smog takes a toll on the economy.

    “If we calculate it in terms of economic value, it could potentially cause economic losses, from a health perspective, of around 40 trillion rupiah (more than $25.2 billion) a year,” said Syuhada, the health analyst.

    “It’s working age people who suffer symptoms of prolonged coughs and colds,” Feni Fitriani Taufik, a pulmonologist at Persahabatan Hospital told The Associated Press. “They used to have it for only three to five days. Now, after two or three weeks the cough still lingers.”

    Solving the pollution issue is complicated.

    Emissions from burning coal, which is highly polluting but relatively cheap, contribute up to a third of Indonesia’s air pollution according to Siti Nurbaya, Indonesia’s Environmental and Forestry Minster. The country has pledged to cut emissions in coming decades, but it still provides most of Indonesia’s energy needs.

    Millions of vehicles and motorcycles spew emissions as workers commute to and within the city. The Indonesian government has called on residents to use public transportation and has given regulation and financial incentives to residents who want to shift from using gas or diesel-fueled vehicles to electric vehicles.

    Public transport remains limited and electric vehicle uptake has been slow: Transportation Minister Budi Karya Sumadi at a national seminar in September said that there were 26,100 electric vehicles and 79,700 electric motorbikes currently operating in Indonesia in 2022— less than one percent of the over 17.2 million registered cars and 125.2 million motorbikes in Indonesia.

    The government is pushing to have more than 530,000 electric vehicles on the road in Indonesia by 2030.

    To make a real dent in the pollution, the government also needs to tighten regulations for emissions from factories and industries in and near Jakarta, according to research from Vital Strategies.

    “They should. Because industry is contributing 30% to 40% of the air pollution in Jakarta, in addition to emissions from transportation,” Syuhada said.

    [ad_2]

    Source link

  • Authorities face calls to declare a hate crime in Vermont shooting of 3 men of Palestinian descent

    Authorities face calls to declare a hate crime in Vermont shooting of 3 men of Palestinian descent

    [ad_1]

    BURLINGTON, Vt. — Vigils for three college students of Palestinian descent who were shot in Vermont over the weekend prompted calls for authorities to recognize the violence as a hate crime, and for unity among the Jewish and Arab communities.

    Jason J. Eaton, 48, was arrested and held without bail on three counts of attempted murder. A not guilty plea was entered on his behalf on Monday.

    The U.S. Department of Justice, along with Vermont authorities, are still investigating whether Saturday’s gunfire on a Burlington street was a hate crime amid an increase in threats against Jewish, Muslim and Arab communities across the U.S. since the Israel-Hamas war began, Attorney General Merrick Garland said. “There is understandable fear in communities across the country,” he said.

    One vigil was held Monday night at Brown University in Rhode Island, where one of the victims, Hisham Awartani, is a student. Participants shouted at school president Christina Paxson as she addressed the crowd, demanding that Brown divest from investments that support Israel, according to media reports.

    Robert Leikend, New England regional director for the American Jewish Committee, called for unity and finding common ground between the Jewish and Arab communities, saying in a statement Monday night that “hate should not beget more hate.”

    He said a vigil after Eaton’s arrest “featured anti-Israel and antisemitic statements from some participants.” He didn’t name the location.

    “The anger is understandable. The finger-pointing is not,” he said.

    The vigil at Brown was closed to media. NBC News reported that Awartani said in a statement read by a professor that as much as he appreciates the love and support of the community, “I am but one casualty in a much wider conflict.”

    The statement read, “Had I been shot in the West Bank, where I grew up, the medical services which saved my life here would have likely been withheld by the Israeli army. The soldier who would have shot me would go home and never be convicted.”

    Awartani, Kinnan Abdalhamid and Tahseen Ali Ahmad, all age 20, were spending their Thanksgiving break in Burlington, and were out for a walk while visiting one of the victims’ relatives when they were confronted by a white man with a handgun, police said. The victims were speaking in a mix of English and Arabic and two of them were also wearing the black-and-white Palestinian keffiyeh scarves when they were shot, Police Chief Jon Murad said.

    Abdalhamid told police he ran away, jumped a fence, and hid behind a house. He eventually knocked on another door, begging the woman who answered to call 911. At that point, he sat down, felt pain, and saw blood, according to an affidavit.

    Two of the students were struck in their torsos, while one was hit in the lower body, Murad said. All three were being treated at the University of Vermont Medical Center, and one faces a long recovery because of a spinal injury, a family member said.

    One of the students has been released from the hospital, according to media reports.

    “I’ve been with them almost constantly since Saturday evening. I’ve been listening to them talk to one another and try to process the events, and I’m blown away by their resilience, by their good humor in the face of these difficult times,” said Rich Price, Awartani’s uncle.

    The three have been friends since first grade at Ramallah Friends School, a private school in the West Bank, and all are “remarkable, distinguished students,” said Rania Ma’ayeh, head of the school.

    Awartani is studying mathematics and archaeology at Brown; Abdalhamid is a pre-med student at Haverford College in Pennsylvania; and Ali Ahmad is studying mathematics and IT at Trinity College in Connecticut, Ma’ayeh said. Awartani and Abdalhamid are U.S. citizens while Ali Ahmad is studying on a student visa, Ma’ayeh said.

    Abdalhamid’s uncle Radi Tamimi, said at a news conference Monday his nephew grew up in the West Bank and “we always thought that that could be more of a risk in terms of his safety and sending him here would be a right decision.

    “We feel somehow betrayed in that decision here and we’re just trying to come to terms with everything,” he said.

    Eaton moved to Burlington over the summer from Syracuse, New York, and legally purchased the gun used in the shooting, Murad told reporters. According to a police affidavit, federal agents found the gun in Eaton’s apartment on Sunday. Eaton came to the door holding his hands, palms up, and told the officers he’d been waiting for them.

    Eaton’s mother, Mary Reed, told the Daily Beast that Eaton, who had held various jobs as a farmer, ski instructor and researcher, had struggled with mental health issues, including depression. But she said he was in “such a good mood” when she saw him on Thanksgiving.

    Syracuse police said Eaton’s name appeared in 37 police reports from 2007 until 2021, but never as a suspect. The cases ranged from domestic violence to larceny, and Eaton was listed as either a complainant or victim in 21 reports, according to Lt. Matthew Malinowski, the department’s public information officer.

    Sarah George, state’s attorney, said that law enforcement officials do not yet have evidence to support a hate crime charge, which under Vermont law must be proven beyond a reasonable doubt. But, she said, “I do want to be clear that there is no question that this was a hateful act.”

    Demonstrations have been widespread and tensions in the U.S. have escalated as the death toll rises in the Israel-Hamas war. A fragile cease-fire between Israel and Hamas was set to continue for two more days past Monday as 11 more hostages were handed over to the Red Cross in Gaza under what was originally a four-day truce deal.

    ___

    Associated Press writers Holly Ramer and Kathy McCormack in Concord, New Hampshire; Lindsay Whitehurst in Washington; and David Sharp in Portland, Maine, contributed to this report.

    [ad_2]

    Source link

  • EU commission to prolong use of glyphosate for 10 more years after member countries fail to agree

    EU commission to prolong use of glyphosate for 10 more years after member countries fail to agree

    [ad_1]

    BRUSSELS — The European Commission will continue the use of the controversial chemical herbicide glyphosate in the European Union for 10 more years after the 27 member countries again failed to find a common position.

    Representatives of EU states were unable to reach a decision last month, and a new vote by an appeal committee was again unconclusive on Thursday. Because of the deadlock, the EU’s executive arm said it will endorse its own proposal and renew the approval of glyphosate for 10 years, with new conditions attached.

    “These restrictions include a prohibition of pre-harvest use as a desiccant and the need for certain measures to protect non-target organisms,” it said in a statement.

    The chemical, which is widely used in the bloc to the great anger of environment groups, had been approved in the EU market until mid-December.

    The Greens political group of the EU Parliament immediately urged the Commission to backpedal and ban the use of glyphosate.

    “We should not gamble with our biodiversity and public health like this,” said Bas Eickhout, the vice chair of the Environment Committee.

    Over the past decade, glyphosate, used in products like the weedkiller Roundup, has been at the heart of heated scientific debate about whether it causes cancer and its possible disruptive effect on the environment. The chemical was introduced by chemical giant Monsanto in 1974 as an effective way of killing weeds while leaving crops and other plants intact.

    Bayer bought Monsanto for $63 billion in 2018 and has been trying to deal with thousands of claims and lawsuits related to Roundup. In 2020, Bayer announced it would pay up to $10.9 billion to settle about 125,000 filed and unfiled claims. Just weeks ago, a California jury awarded $332 million to a man who sued Monsanto contending that his cancer was related to decades of using Roundup.

    The France-based International Agency for Research on Cancer, which is part of the World Health Organization, classified glyphosate as a “probable human carcinogen” in 2015.

    But the EU’s food safety agency paved the way for a 10-year extension when it said in July it “did not identify critical areas of concern” in the use of glyphosate.

    The U.S. Environmental Protection Agency found in 2020 that the herbicide did not pose a health risk to people, but a federal appeals court in California last year ordered the agency to reexamine that ruling, saying it wasn’t supported by enough evidence.

    EU member states are responsible for authorizing the use of products in their national markets, following a safety evaluation.

    The 10-year extension proposed by the European Commission required a “qualified majority,” defined as 55% of the 27 members representing at least 65% of the total EU population of some 450 million people. Several member states abstained and that was not achieved, leaving the final say to the EU’s executive arm.

    In France, President Emmanuel Macron had committed to ban glyphosate before 2021 but has since backpedaled. Germany, the EU’s biggest economy, plans to stop using it from next year, but the decision could be challenged. Luxembourg’s national ban, for instance, was overturned in court earlier this year.

    Greenpeace has called on the EU to reject the market reapproval, citing studies indicating that glyphosate may cause cancer and other health problems and could also be toxic to bees. The agroindustry sector, however, says there are no viable alternatives.

    [ad_2]

    Source link